Ergotamine-Caffeine (Ergotamine Tartrate/Caffeine) Patent Expiration, LOE Window & CMS Spending

Ergotamine-Caffeine (Ergotamine Tartrate/Caffeine) by Cintex Services: Off-Patent Genericized (AB Competition), 0 AB generics, $2.7M 2024 CMS Part D & Medicaid spend, and $1,508 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCintex Services
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.7M
2024 Medicare Part D Spend$2.7M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,508 intro WAC)